Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

PDS Biotechnology Corp

PDSB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.30

▲ +36.36%

Market Cap $16.79M · Vol 13.83M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$16.79M

Micro Cap

Div Yield

N/A

EPS Growth

+39.19%

YoY

RSI (14)

79.75

Momentum

Beta

1.47

vs Market

52W High

$1.55

80.58% below

52W Low

$0.20

53.69% above

Volume

13.83M

Avg 664.60K

P/B

4.57

Price-to-book

ROE

N/A

Return on equity

Free Float

98.49%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, PDS Biotechnology Corp (PDSB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PDSB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+40.19%

-61.31%

-70.00%

-55.42%

YTD

-61.03%

-74.36%

-94.84%

-98.04%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-34,495,510.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-94.04% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.57
P/FCF	N/A
EPS Growth	+39.19%
Outstanding Shares	55.97M

Technical Indicators

50-Day SMA	$0.54
200-Day SMA	$0.81
RSI (14)	79.75
Beta	1.47
52-Week High	$1.55
52-Week Low	$0.20

Volume Today	13.83M
Avg Daily Volume (30D)	664.60K
Relative Volume	20.80x
Volatility (10D)	152.61
Volatility (30D)	316.35
Free Float	98.49%

Analyst Consensus

BUY

Current Price $0.30

Mean Target $4.17

52W Low$0.20 52W High$1.55

Current

Target

$0.20 $1.55

Current Analyst target

+1,288.89% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG004NCDKL7

ISINUS70465T1079

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -0.41% ARGX argenx SE -2.52% INSM Insmed Inc -1.11% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.